InfinixBio Announces New Pharmacokinetics Division

InfinixBio Announces New Pharmacokinetics Division

Ohio Biotech Company Continues to Grow, Expanding Service Offerings with the Addition of Their New Pharmacokinetics Division

Columbus, OH (March 2023) – InfinixBio, an Ohio-based biotechnology company helping companies advance product development through the regulatory approval process, announces the launch of their new Pharmacokinetics Division.

InfinixBio’s expertise extends to study design and execution, GLP sample bioanalysis for biotherapeutics and small molecule therapeutics using immunoassay and LC-MS/MS quantification, and pharmacokinetic data analysis using noncompartmental analysis (NCA) or multi-compartmental modeling. Launching their new pharmacokinetics division enables InfinixBio to support the advancement of compounds from discovery through new drug applications.

“We are extremely pleased to expand our service offerings to provide more comprehensive support through the entire drug development pipeline,” said Nick Henderson, CEO of InfinixBio. “This new division will allow us to provide study design and data analysis services that dovetail seamlessly with our fully-established bioproduction, early drug development, and bioanalysis services, allowing us to deliver a more unified product development journey for our clients.”

InfinixBio’s team of scientists, researchers, and drug development experts utilize their Rapid Innovate Model™, a unique and common-sense approach to accelerate product development that enables an accelerated path to market.

About InfinixBio

InfinixBio is a full-service, cost-effective CRO that partners with clients to expand capabilities and meet critical milestones for FDA drug and device regulatory requirements. Its cross-functional interdisciplinary team comprises expert scientists and PhDs operating in multiple BSL Level II labs.

InfinixBio’s Rapid Innovate ModelTM helps companies quickly accelerate technology from early development through preclinical and into the clinical trial phase. InfinixBio currently has over 50 patents, either issued or pending.

To learn more about InfinixBio, please visit

Media and Partnership Inquiries Contact

Please contact Nick Henderson to discuss this at

Looking for a trusted partner for your pre-clinical toxicology studies?

Our experienced lab team is here to help. Reach out today to learn more.